Kevin Harrington

Head of Division of Radiotherapy and Imaging

Institute of Cancer Research

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kevin Harrington is the Head of the Division of Radiotherapy and Imaging at the Institute of Cancer Research in the United Kingdom. His research focuses on innovative treatment strategies for head and neck cancers, with recent publications highlighting clinical studies on therapies combining radiotherapy with immune checkpoint inhibitors and novel agents. He is actively involved in advancing the understanding of patient experiences and treatment efficacy in this specialized field.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (5)

Helen A McNair

Professor of Translational therapeutic radiography and lead clinical academic radiographer

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

UNITED KINGDOM

View details

Konrad Klinghammer

charité university hospital

GERMANY

View details

Christophe Le Tourneau

Head of Early Phase Clinical Trials

Institut Curie

FRANCE

View details

Joshua Brody

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Tanguy Seiwert

Johns Hopkins University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kevin Harrington

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors

Patient experience of head and neck treatment on a 1.5 T MR-Linac: is the ATS-lite adaptive solution tolerable?

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

Harnessing Radiation Biology to Increase Cancer Cure Rates

STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study

Collaborators (5)

Helen A McNair

Konrad Klinghammer

Christophe Le Tourneau

Joshua Brody

Tanguy Seiwert

Make your next move.